Virtual Network's Login.
ESH Gold Institutional Partner
ESH Gold Institutional Partner
Despite the impressive clinical results of tyrosine kinase inhibitors in the management of patients with CML, many unresolved questions remain. This meeting brings together scientists with new data on the cellular, molecular and immune biology of CML, some of which may eventually translate into new therapeutic approaches that would enable the clinician to discontinue therapy with the expectation that the leukaemia would not recur.
| Friday, September 24, 2010 | ||
| 08h15 - 08h20 | Welcome to Washington | J. Barrett (Bethesda) |
| 08h20 - 08h45 |
Rowley Lecture - Chair: J.Goldman (London) |
M. Talpaz (Ann Arbor) |
| Session I: Stem Cell Biology - Chair: John Goldman (London) | ||
| 08h45 - 09h00 | Ph-negative neoplasms | T. Green (Cambridge, UK) |
| 09h00 - 09h15 | Ph + quiescent cells | P. Neviani (Columbus) |
| 09h15 - 09h30 | Oncogene addiction in CML | M. Deininger (Portland) |
| 09h30 - 09h45 | Relevance of BCR-ABL for survival of LSC | V. Helgason (Glasgow) |
| 09h45 - 10h00 | The role of Musashi 2 in myeloid leukemia | M. Kharas (Boston) |
| 10h00 - 10h15 | Regulation of survival in normal and CML cells | F. Pellicano (Glasgow) |
| 10h15 - 10h30 | Altered trafficking and niche interactions in a CML mouse model | R. Bhatia (Duarte) |
| 10h30 - 10h45 | ScITAxTRE-BCR-ABL inducible mouse model | D. Reynaud (San Francisco) |
| 10h45 - 11h00 | BCR-ABL in Sca1 cells | C. Vicente-Duenas (Salamanca) |
| 11h00 - 11h30 | Break with poster viewing | |
| Session II: Targeting stem cells - Chair: Junia Melo (Adelaide) | ||
| 11h30 - 11h45 | IL1RAP | T. Fioretos (Lund) |
| 11h45 - 12h00 | Targeting antiapoptotic proteins to eradicate quiescent CML progenitor cells | B. Carter (Houston) |
| 12h00 - 12h15 | Beta arrestin | M. Fereshteh (Durham) |
| 12h15 - 12h30 | NFkB in myeloid and lymphoid transformation and leukemogenesis | R. Van Etten (Boston) |
| 12h30 - 12h45 | Hedgehog pathway | M. Copland (Glasgow) |
| 12h45 - 13h00 | Targeting CML progenitors with ABL & JAK2 inhibitors | X. Jiang (Vancouver) |
| 13h00 - 14h30 | Lunch with poster viewing | |
| 14h30 - 15h30 | Brief Oral Session A - Chair: Jerry Radich (Seattle) | |
| Abstract # 1 | R. Arlinghaus (Houston) | |
| Abstract # 3 | E. Bolton (Philadelphia) | |
| Abstract # 36 | S. Li (Worcester) | |
| Abstract # 15 | Y. Dasgupta (Philadelphia) | |
| Abstract # 19 | C. Drullion (Bordeaux) | |
| Abstract # 5 | T. Brummendorf (Aachen) | |
| Abstract # 37 | L. Li (Duarte) | |
| Abstract # 17 | C. Quintarelli (Naples) | |
| Abstract # 43 | F. Nicolini ( Lyon) | |
| Session III: Mathematical modeling - Chair : Tessa Holyoake (Glasgow) | ||
| 15h30 - 15h45 | Mathematical modeling of diversity in pre-existing resistance to BCR-ABL inhibitors | J. Foo (Cambridge, USA) |
| 15h45 - 16h00 | Response dynamics of imatinib and nilotinib | D. Dingli (Rochester, MN) |
| 16h00 - 16h15 | Short Break | |
| Session IV: Kinase effects & Genomic instability - Chair: Danilo Perrotti (Columbus) | ||
| 16h15 - 16h30 | Molecular mechanism of leukemogenicity | O. Hantschel (Vienna) |
| 16h30 - 16h45 | Ikaros alterations in Ph+ALL | C. Mullighan (Memphis) |
| 16h45 - 17h00 | Mutator phenotype of BCR-ABL | Y. Maru (Tokyo) |
| 17h00 - 17h15 | Mismatch repair protein dysfunction | T. Stoklosa (Warsaw) |
| 17h15 - 17h30 | Next generation sequencing identifies novel molecular alterations in PH+ALL | I. Iacobucci (Bologna) |
| 17h30 - 17h45 | Mechanisms of genomic instability in CML stem cells | P. Kopinski (Philadelphia) |
|
Saturday, September 25, 2010 |
||
| Session V: Immunologic aspects of CML - Chair: Tessa Holyoake (Glasgow) | ||
| 08h30 - 08h45 | Target for immunotherapy in CML | J. Barrett (Bethesda) |
| 08h45 - 09h00 | WT1 | D. Scheinberg (New York) |
| 09h00 - 09h15 | BMI 1 | A. Yong (Bethesda) |
| 09h15 - 09h30 | NK gene polymorphisms in CML | K. Rezvani (London) |
| 09h30 - 10h00 | Break with poster viewing | |
| Session VI: Resistance including TKI mutations - Chair: Angelo Carella (Genoa) | ||
| 10h00 - 10h15 | B-catenin involved in resistance to imatinib | J. Wang (San Diego) |
| 10h15 - 10h30 | PI3K in maintaining LSC | A. Hirao (Kanagawa) |
| 10h30 - 10h45 | Massively parellel sequencing in CML | S. Soverini (Bologna) |
| 10h45 - 11h00 | Mutations relevant to 2G-TKI | S. Branford (Adelaide) |
| 11h00 - 11h15 | NRF2 in imatinib resistance | F. Rassool (Baltimore) |
| 11h15 - 11h30 | Targeting kinase and BCL6 dependent feedback | M. Müschen (Los Angeles) |
| 11h30 - 12h30 | Brief Oral Session B - Chair: Tomasz Skorski (Philadelphia) | |
| Abstract # 24 | H. Ming (London) | |
| Abstract # 27 | D.H. D. Kim (Seoul) | |
| Abstract # 39 | A. Morotti (Turin) | |
| Abstract # 44 | T. O´Hare (Portland) | |
| Abstract # 45 | E. Pietras (San Francisco) | |
| Abstract # 20 | C. Quintarelli (Naples) | |
| Abstract # 30 | J. Khorashad (London) | |
| Abstract # 52 | A. Turhan (Poitiers) | |
| Abstract # 47 | A. Reid (London) | |
|
12h30 - 13h30 |
Lunch with poster viewing | |
| Session VII: Progession to advanced phase - Chair: François Guillot (Poitiers) | ||
| 13h30 - 13h45 | Lin28 in malignant transformation | J. Power (Boston) |
| 13h45 - 14h00 | Model of blastic crisis | J. Rusert (San Diego) |
| 14h00 - 14h15 | PP2A | C. Lucas (Liverpool) |
| 14h15 - 14h30 | Developmental mechanisms in CML progression | T. Reya (Durham) |
| Session VIII: Diagnostic tests and prognostic markers - Chair: Timothy Hughes (Adelaide) | ||
| 14h30 - 14h45 | Single cell genotyping | J. Radich (Seattle) |
| 14h45 - 15h00 | Mechanisms of resistance other than KD mutations | F.-X. Mahon (Bordeaux) |
| 15h00 - 15h15 | DNA based PCR for monitoring | A. Morley (Adelaide) |
| 15h15 - 15h30 | Antibodies to BCR-ABL | H. Wai (San Jose) |
| 15h30 - 15h45 | Definitions of CMR | A. Hochhaus (Jena) |
| 15h45 - 16h00 | Patient specific approach to optimising TKI therapy | D. White (Adelaide) |
| 16h00 - 16h15 | Prognostic value of MDR1 | M. Müller (Mannheim) |
| 16h15 - 16h45 | Break with poster viewing | |
| 16h45 - 17h45 | Brief Oral Session C - Chair: Simona Soverini (Bologna) | |
| Abstract # 6 | A. Carella (Genoa) | |
| Abstract # 53 | D. Yeung (Adelaide) | |
| Abstract # 18 | H. De Lavallade (London) | |
| Abstract # 54 | B. Zhang (Duarte) | |
| Abstract # 55 | Y. Zhao (Suzhou) | |
| Abstract # 48 | P. Rousselot (Chesnay) | |
| Abstract # 40 | S. Mustjoki (Helsinki) | |
| Abstract # 13 | D. Cilloni (Turin) | |
|
Sunday, September 26, 2010 |
||
| Session IX: New drugs in development - Chair: Rudiger Hehlmann | ||
| 08h30 - 08h45 | Bosutinib | C. Gambacorti (Monza) |
| 08h45 - 09h00 | Ariad, DCC 2036, other new agents | J. Cortes (Houston) |
| 09h00 - 09h15 | Omacetaxine | J. Apperley (London) |
| 09h15 - 09h30 | Smo inhibitors | G. Martinelli (Bologna) |
| 09h30 - 09h45 | Break | |
|
Session X: Current clinical controversies - Chair: Michele Baccarani (Bologna) |
||
| 09h45 - 10h15 | Is MMR better than CCyR ? | G. Rosti (Bologna) & G. Saglio (Turin) |
| 10h15 - 10h45 | Starting with imatinib or 2G-TKI ? | J. Cortes (Houston) & C. Schiffer (Detroit) |
| 10h45 - 11h15 | Should interferon come back now? | F. Guilhot (Poitiers) & A. Hochhaus (Jena) |
| 11h15 - 11h30 | Does CMR have any real relevance? | T. Hughes (Adelaide) |
| 11h30 - 11h45 | The ideal clinical trial for the coming decade | S. O’Brien (Newcastle) |
| 11h45 - 12h00 | Closing comments including short musical interlude | J. Goldman (London) & C. Schiffer (Detroit) |
Grand Hyatt Washington DC
1000 H Street, NW
Washington, DC 20001
